117 related articles for article (PubMed ID: 6971912)
1. Characterization of a new mode of defective ristocetin-induced platelet aggregation.
Baugh RF; Hougie C
J Lab Clin Med; 1981 Jun; 97(6):864-80. PubMed ID: 6971912
[TBL] [Abstract][Full Text] [Related]
2. Family studies of patients with reduced ristocetin aggregation and abnormalities of factor VIII and/or platelet function.
Ekert H; Ananthakrishnan R; Muntz RH; Dowling S; D'Souza S
Thromb Haemost; 1976 Aug; 36(1):78-85. PubMed ID: 1087478
[TBL] [Abstract][Full Text] [Related]
3. [Ristocetin induced platelet aggregation in children with nephrotic syndrome].
Taira K; Okajima C; Yamashita T; Kawahara S; Matsunaga T; Nakajima M; Kamitsuji H
Nihon Jinzo Gakkai Shi; 1990 Jun; 32(6):659-66. PubMed ID: 2214316
[TBL] [Abstract][Full Text] [Related]
4. Laboratory diagnosis and molecular classification of von Willebrand disease.
Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of ristocetin-induced platelet agglutination by vancomycin.
Moake JL; Cimo PL; Peterson DM; Roper P; Natelson EA
Blood; 1977 Sep; 50(3):397-406. PubMed ID: 301760
[TBL] [Abstract][Full Text] [Related]
6. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences.
Michiels JJ; Gadisseur A; Budde U; Berneman Z; van der Planken M; Schroyens W; van de Velde A; van Vliet H
Semin Thromb Hemost; 2005 Nov; 31(5):577-601. PubMed ID: 16276467
[TBL] [Abstract][Full Text] [Related]
7. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
[TBL] [Abstract][Full Text] [Related]
8. Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management.
Michiels JJ; Budde U; van der Planken M; van Vliet HH; Schroyens W; Berneman Z
Best Pract Res Clin Haematol; 2001 Jun; 14(2):401-36. PubMed ID: 11686107
[TBL] [Abstract][Full Text] [Related]
9. Impaired ristocetin aggregation in myeloma due to binding of the aggregating agent by monoclonal protein--presentation of a case.
László E; Péterfy M; Puskás E
Folia Haematol Int Mag Klin Morphol Blutforsch; 1987; 114(6):852-6. PubMed ID: 2453415
[TBL] [Abstract][Full Text] [Related]
10. Laboratory diagnosis and monitoring of desmopressin treatment of von Willebrand's disease by flow cytometry.
Giannini S; Mezzasoma AM; Leone M; Gresele P
Haematologica; 2007 Dec; 92(12):1647-54. PubMed ID: 18055988
[TBL] [Abstract][Full Text] [Related]
11. Plasma components which interfere with ristocetin-induced platelet aggregation.
Baugh RF; Brown JE; Hougie C
Thromb Diath Haemorrh; 1975 Jun; 33(3):540-6. PubMed ID: 1080300
[TBL] [Abstract][Full Text] [Related]
12. Interaction of platelets, von Willebrand factor, and ristocetin during platelet agglutination.
Moake JL; Olson JD; Troll JH; Weinger RS; Peterson DM; Cimo PL
J Lab Clin Med; 1980 Jul; 96(1):168-84. PubMed ID: 6967100
[TBL] [Abstract][Full Text] [Related]
13. Acquired type 2A von Willebrand disease in chronic myelocytic leukemia.
Mohri H; Tanabe J; Yamazaki E; Yoshida M; Harano H; Matsuzaki M; Motomura S; Okubo T
Hematopathol Mol Hematol; 1996; 10(3):123-33. PubMed ID: 8878731
[TBL] [Abstract][Full Text] [Related]
14. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
Gadisseur A; van der Planken M; Schroyens W; Berneman Z; Michiels JJ
Acta Haematol; 2009; 121(2-3):145-53. PubMed ID: 19506361
[TBL] [Abstract][Full Text] [Related]
15. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
[TBL] [Abstract][Full Text] [Related]
16. Classification and characterization of hereditary types 2A, 2B, 2C, 2D, 2E, 2M, 2N, and 2U (unclassifiable) von Willebrand disease.
Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van de Velde A; van Vliet H
Clin Appl Thromb Hemost; 2006 Oct; 12(4):397-420. PubMed ID: 17000885
[TBL] [Abstract][Full Text] [Related]
17. Enhanced ristocetin-induced von Willebrand factor binding to platelet glycoprotein Ib in patients with steroid-responsive nephrotic syndrome.
Taira K; Kamitsuji H; Okajima C; Fujimura Y
Haemostasis; 1990; 20(4):219-28. PubMed ID: 2242824
[TBL] [Abstract][Full Text] [Related]
18. Platelet-collagen interaction: inhibition by ristocetin and enhancement by von Willebrand factor-platelet binding.
LaDuca FM; Bettigole RE; Bell WR; Robson EB
Blood; 1986 Oct; 68(4):927-37. PubMed ID: 3489493
[TBL] [Abstract][Full Text] [Related]
19. Measurement of von Willebrand factor binding to a recombinant fragment of glycoprotein Ibalpha in an enzyme-linked immunosorbent assay-based method: performances in patients with type 2B von Willebrand disease.
Caron C; Hilbert L; Vanhoorelbeke K; Deckmyn H; Goudemand J; Mazurier C
Br J Haematol; 2006 Jun; 133(6):655-63. PubMed ID: 16704443
[TBL] [Abstract][Full Text] [Related]
20. Mapping and functional studies of two alloantibodies developed in patients with type 3 von Willebrand disease.
Tout H; Obert B; Houllier A; Fressinaud E; Rothschild C; Meyer D; Girma JP
Thromb Haemost; 2000 Feb; 83(2):274-81. PubMed ID: 10739386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
